Genetic Factors and Prostate Cancer Conversion From Active Surveillance to Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment
HGG Adv 2022 Jan 13;3(1)100070, Y Jiang, TJ Meyers, AA Emeka, LF Cooley, PR Cooper, N Lancki, I Helenowski, L Kachuri, DW Lin, JL Stanford, LF Newcomb, S Kolb, A Finelli, NE Fleshner, M Komisarenko, JA Eastham, B Ehdaie, N Benfante, CJ Logothetis, JR Gregg, CA Perez, S Garza, J Kim, LS Marks, M Delfin, D Barsa, D Vesprini, LH Klotz, A Loblaw, A Mamedov, SL Goldenberg, CS Higano, M Spillane, E Wu, HB Carter, CP Pavlovich, M Mamawala, T Landis, PR Carroll, JM Chan, MR Cooperberg, JE Cowan, TM Morgan, J Siddiqui, R Martin, EA Klein, K Brittain, P Gotwald, DA Barocas, JR Dallmer, JB Gordetsky, P Steele, SD Kundu, J Stockdale, MJ Roobol, LDF Venderbos, MG Sanda, R Arnold, D Patil, CP Evans, MA Dall'Era, A Vij, AJ Costello, K Chow, NM Corcoran, S Rais-Bahrami, C Phares, DS Scherr, T Flynn, RJ Karnes, M Koch, CR Dhondt, JB Nelson, D McBride, MS Cookson, KL Stratton, S Farriester, E Hemken, WM Stadler, T Pera, D Banionyte, FJ Bianco, IH Lopez, S Loeb, SS Taneja, N Byrne, CL Amling, A Martinez, L Boileau, FD Gaylis, J Petkewicz, N Kirwen, BT Helfand, J Xu, DM Scholtens, WJ Catalona, JS WitteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.